Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

The 10-year survival rate of people diagnosed with cancer in Japan in 2012 came to 54.0%, up slightly from 53.5% for those ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...